Cencora, Inc. (COR)
Automate Your Wheel Strategy on COR
With Tiblio's Option Bot, you can configure your own wheel strategy including COR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol COR
- Rev/Share 1633.9741
- Book/Share 11.4033
- PB 30.5861
- Debt/Equity 4.1615
- CurrentRatio 0.9047
- ROIC 0.1274
- MktCap 60592654149.0
- FreeCF/Share 5.8907
- PFCF 53.0775
- PE 31.9232
- Debt/Assets 0.1114
- DivYield 0.007
- ROE 1.9632
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | COR | Wells Fargo | Equal Weight | Overweight | -- | $337 | June 3, 2025 |
| Resumed | COR | Mizuho | -- | Outperform | -- | $280 | Dec. 4, 2024 |
| Downgrade | COR | BofA Securities | Buy | Neutral | $275 | $245 | Sept. 18, 2024 |
News
Cencora (COR) Earnings Expected to Grow: Should You Buy?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.
Read More
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Here, we discuss three medical device stocks ,COR, HIMS and PBH, that offer cheap valuations, making them attractive bets amid tariff risks.
Read More
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Top 3 MedTech Stocks to Weather the Trump Tariff Turbulence
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Negative
In the present market turbulence, investors may want to consider discounted stocks, such as FMS, PAHC and COR.
Read More
Sellers Rule The Roost Amid Tariff Wars, But This Stock Hits A High
Published: April 04, 2025 by: Investors Business Daily
Sentiment: Positive
Cencora hit an all-time high on Friday. The post Sellers Rule The Roost Amid Tariff Wars, But This Stock Hits A High appeared first on Investor's Business Daily.
Read More
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.
Read More
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.
Read More
Cencora (COR) is a Top-Ranked Growth Stock: Should You Buy?
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
3 Medical Services Industry Stocks to Buy as AI Fuels Growth
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Medical - Services industry is undergoing a transformation on massive artificial intelligence adoption. COR, DOCS and MD are set to gain the most.
Read More
Cencora (COR) is a Top-Ranked Value Stock: Should You Buy?
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here is Why Growth Investors Should Buy Cencora (COR) Now
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Here's Why You Should Add Cencora Stock to Your Portfolio Now
Published: March 11, 2025 by: Zacks Investment Research
Sentiment: Positive
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Read More
Why Is Cencora (COR) Up 3.1% Since Last Earnings Report?
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
Read More
Scoop Up These 3 GARP Stocks to Receive Handsome Returns
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. SFM, COR and AXP are some stocks that hold promise.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook Cencora (COR)
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Cencora: Higher Potential Returns After Reduced Walgreens Stake
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging population. The company has a strong economic moat, low leverage, BBB+ credit rating, and an active share repurchase program, enhancing shareholder returns. Strategic acquisitions like Retina Consultants of America position Cencora for long-term success, with management guiding for 10% annual EPS growth.
Read More
3 GARP Stocks That Investors Can Scoop Up for Maximum Returns
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. AXP, COR and TPX hold promise.
Read More
About Cencora, Inc. (COR)
- IPO Date 1995-04-04
- Website https://www.amerisourcebergen.com
- Industry Medical - Distribution
- CEO Robert P. Mauch PharmD
- Employees 42000